Multifactorial Regulation of Myometrial Contractility During Pregnancy and Parturition
Open Access
- 25 October 2019
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 10, 714
Abstract
The steroid hormones progesterone (P4) and estradiol-17β (E2), produced by the placenta in humans and the ovaries in rodents, serve crucial roles in the maintenance of pregnancy, and the initiation of parturition. Because of their critical importance for species survival, the mechanisms whereby P4 and its nuclear receptor (PR) maintain myometrial quiescence during pregnancy, and for the decline in P4/PR and increase in E2/estrogen receptor (ER) function leading to parturition, are multifaceted, cooperative, and redundant. These actions of P4/PR include: (1) PR interaction with proinflammatory transcription factors, nuclear factor κB (NF-κB), and activating protein 1 (AP-1) bound to promoters of proinflammatory and contractile/contraction-associated protein (CAP) genes and recruitment of corepressors to inhibit NF-κB and AP-1 activation of gene expression; (2) upregulation of inhibitors of proinflammatory transcription factor activation (IκBα, MKP-1); (3) induction of transcriptional repressors of CAP genes (e.g., ZEB1). In rodents and most other mammals, circulating maternal P4 levels remain elevated throughout most of pregnancy and decline precipitously near term. By contrast, in humans, circulating P4 levels and myometrial PR levels remain elevated throughout pregnancy and into labor. However, even in rodents, wherein P4 levels decline near term, P4 levels remain higher than the Kd for PR binding. Thus, parturition is initiated in all species by a series of molecular events that antagonize the P4/PR maintenance of uterine quiescence. These events include: direct interaction of inflammatory transcription factors (e.g., NF-κB, AP-1) with PR; increased expression of P4 metabolizing enzymes; increased expression of truncated/inhibitory PR isoforms; altered expression of PR coactivators and corepressors. This article will review various mechanisms whereby P4 acting through PR isoforms maintains myometrial quiescence during pregnancy as well as those that underlie the decline in PR function leading to labor. The roles of P4- and E2-regulated miRNAs in the regulation and integration of these mechanisms will also be considered.Keywords
Funding Information
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (5-P01-HD0087150)
- National Heart, Lung, and Blood Institute
- Burroughs Wellcome Fund
- National Natural Science Foundation of China (81622020)
This publication has 172 references indexed in Scilit:
- MicroRNA-200a serves a key role in the decline of progesterone receptor function leading to term and preterm laborProceedings of the National Academy of Sciences, 2012
- Steroid receptor coactivators 1, 2, and 3: Critical regulators of nuclear receptor activity and steroid receptor modulator (SRM)-based cancer therapyMolecular and Cellular Endocrinology, 2012
- The ZEB1/miR‐200 feedback loop controls Notch signalling in cancer cellsThe EMBO Journal, 2011
- miR-200 family and targets, ZEB1 and ZEB2, modulate uterine quiescence and contractility during pregnancy and laborProceedings of the National Academy of Sciences, 2010
- Inhibiting NF-κB activation by small molecules as a therapeutic strategyBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2010
- Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) familyNature Reviews Cancer, 2009
- Integration of endocrine and mechanical signals in the regulation of myometrial functions during pregnancy and labourEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2009
- A reciprocal repression between ZEB1 and members of the miR‐200 family promotes EMT and invasion in cancer cellsEMBO Reports, 2008
- MicroRNA regulation of cyclooxygenase-2 during embryo implantationProceedings of the National Academy of Sciences, 2007
- Identification and characterization of a lysophosphatidylcholine acyltransferase in alveolar type II cellsProceedings of the National Academy of Sciences, 2006